Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA.
J Clin Pharm Ther. 2012 Jun;37(3):254-9. doi: 10.1111/j.1365-2710.2011.01302.x. Epub 2011 Sep 28.
Type 2 diabetes mellitus (T2DM) is a progressive multisystem disease, and less than half the population with T2DM has achieved the recommended glycosylated haemoglobin A1c goal. We aim to present key points to consider when selecting pharmacotherapy for the management of T2DM. The selection of pharmacotherapy is discussed within the context of the underlying pathophysiology of T2DM, currently available treatment options highlighting newer agents and current clinical guidelines.
Combination therapy regimens that target the multiple organ systems involved in the pathophysiology of T2DM can be developed based on the mechanism of action (MOA) of each class of agents. We compare the pathophysiology of T2DM with the MOA of the currently available non-insulin therapeutic options.
Combination therapy that efficiently and effectively targets multiorgan correction with the least risk for serious adverse events, such as hypoglycaemia and drug interactions, is needed when initial treatment fails to achieve the desired clinical outcomes. Newer agents, now incorporated in treatment guidelines, increase the range of options available to the clinician.
2 型糖尿病（T2DM）是一种进行性多系统疾病，不到一半的 T2DM 患者达到了推荐的糖化血红蛋白 A1c 目标。我们旨在提出在选择治疗 T2DM 的药物治疗时需要考虑的要点。药物治疗的选择是在 T2DM 的潜在病理生理学的背景下讨论的，突出了新的药物和当前的临床指南。
可以根据每个类别的药物的作用机制（MOA）开发针对 T2DM 病理生理学中涉及的多个器官系统的联合治疗方案。我们将 T2DM 的病理生理学与目前可用的非胰岛素治疗选择的 MOA 进行比较。
当初始治疗未能达到预期的临床结果时，需要一种能够有效地、有效地针对多器官纠正且低血糖和药物相互作用等严重不良事件风险最小的联合治疗方法。现在纳入治疗指南的新药物增加了临床医生可用的选择范围。
